Parkman Healthcare Partners LLC Boosts Holdings in ESSA Pharma Inc. (NASDAQ:EPIX)

Parkman Healthcare Partners LLC raised its holdings in ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) by 37.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 345,902 shares of the company’s stock after purchasing an additional 93,830 shares during the period. Parkman Healthcare Partners LLC owned 0.78% of ESSA Pharma worth $2,096,000 at the end of the most recent reporting period.

ESSA Pharma Price Performance

Shares of EPIX opened at $1.75 on Wednesday. The firm has a market cap of $77.65 million, a price-to-earnings ratio of -2.82 and a beta of 1.62. The business’s 50 day moving average is $3.97 and its two-hundred day moving average is $4.96. ESSA Pharma Inc. has a 52-week low of $1.40 and a 52-week high of $11.67.

Insider Activity at ESSA Pharma

In other ESSA Pharma news, major shareholder Growth N. V. Biotech sold 7,879,583 shares of the business’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $1.53, for a total transaction of $12,055,761.99. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 7,880,971 shares of company stock valued at $12,064,111 over the last ninety days. Corporate insiders own 14.70% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on EPIX. Piper Sandler cut ESSA Pharma from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $15.00 to $2.00 in a report on Monday, November 4th. Jefferies Financial Group downgraded shares of ESSA Pharma from a “buy” rating to a “hold” rating in a research note on Monday, November 4th. Finally, Oppenheimer lowered shares of ESSA Pharma from an “outperform” rating to a “market perform” rating in a report on Monday, November 4th.

ESSA Pharma Company Profile

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company’s lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.